New hope for AML patients: oral drug aims to keep remission going
NCT ID NCT07458542
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at how well and how safely oral azacitidine (ONUREG) works as maintenance therapy for Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants cannot or choose not to have a stem cell transplant. Researchers will track how long patients stay cancer-free and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral azacitidine (ONUREG)
What this could lead to
If successful, this could confirm that oral azacitidine helps keep AML in remission longer for patients who cannot have a stem cell transplant.
What could go wrong
This is a small, real-world study in Hong Kong with only 44 participants, so results may not apply broadly. Side effects like low blood counts or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Hong Kong
Hong Kong, China